Further research and larger-scale clinical trials are warranted to validate these initial findings and determine the optimal dosing and treatment regimens for maximizing the therapeutic benefits of HDAC inhibitors in HCC patients. This evidence concerns the gene HDAC9 and hepatocellular carcinoma.